Department of Endocrinology, Tungwah Hospitalof Sun Yat-Sen University, Dongguan, China.
Physiol Res. 2021 Apr 30;70(2):203-211. doi: 10.33549/physiolres.934547. Epub 2021 Mar 8.
Asprosin, coiled-coil domain-containing 80(CCDC80) and angiopoietin-like4(ANGPTL4) are newly discovered adipocytokine that affects glucose tolerance, insulin resistance and cardiovascular diseases. The goal of this study was to investigate if a relationship exists among asprosin, CCDC80 and ANGPTL4 and inflammatory bowel disease (IBD). Fifty subjects with newly diagnosed IBD and fifty healthy individuals were enrolled. Patients were treated with standard therapies for 3 months. Plasma asprosin, CCDC80 and ANGPTL4 levels were measured with enzyme-linked immunosorbent assay. High resolution ultrasound was used to measure brachial artery diameter at rest, after reactive hyperemia (flow-mediated dilation, FMD) and after sublingual glyceryltrinitrate.Compare with healthy individuals, plasma CCDC80,erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels and homeostasis modelassessment of insulin resistance (HOMA-IR) were significantly higher (p < 0.05, respectively), whereas plasma asprosin,ANGPTL4 levels and FMD were significantly lower inboth UC and CD patients(p <0.05). Plasma CCDC80 levels were significantly higher in patients with CD (p<0.05), while plasma asprosin and ANGPTL4 levels were lower (p<0.05) as compared with those in patients with UC. Standard therapies increased plasma asprosin, ANGPTL4 levels and FMD in both UC and CD (p<0.05),UC and CD patientswhile decreased plasma CCDC80, ESR, CRP levels and HOMA-IR (p<0.05). The changes in HOMA-IR and FMD were correlated with the changes in plasma asprosin, CCDC80 and ANGPTL4 levels over the study period (p<0.05). Plasma asprosin, CCDC80 and ANGPTL4 levels may be applied as a significant marker for early stage of insulin resistance and atherosclerosis in IBD, especially of CD.
阿普索辛、卷曲螺旋结构域蛋白 80（CCDC80）和血管生成素样蛋白 4（ANGPTL4）是新发现的脂肪细胞因子，可影响葡萄糖耐量、胰岛素抵抗和心血管疾病。本研究旨在探讨阿普索辛、CCDC80 和 ANGPTL4 与炎症性肠病（IBD）之间是否存在关系。招募了 50 例新诊断为 IBD 的患者和 50 名健康个体。患者接受标准治疗 3 个月。采用酶联免疫吸附试验测定血浆阿普索辛、CCDC80 和 ANGPTL4 水平。使用高分辨率超声测量静息时、反应性充血后（血流介导的扩张，FMD）和舌下含服甘油三硝酸酯后肱动脉直径。与健康个体相比，UC 和 CD 患者的血浆 CCDC80、红细胞沉降率（ESR）、C 反应蛋白（CRP）水平和稳态模型评估的胰岛素抵抗（HOMA-IR）显著升高（p<0.05），而血浆阿普索辛、ANGPTL4 水平和 FMD 显著降低（p<0.05）。CD 患者的血浆 CCDC80 水平显著升高（p<0.05），而 UC 患者的血浆阿普索辛和 ANGPTL4 水平较低（p<0.05）。标准治疗可增加 UC 和 CD 患者的血浆阿普索辛、ANGPTL4 水平和 FMD（p<0.05），同时降低血浆 CCDC80、ESR、CRP 水平和 HOMA-IR（p<0.05）。HOMA-IR 和 FMD 的变化与研究期间血浆阿普索辛、CCDC80 和 ANGPTL4 水平的变化相关（p<0.05）。血浆阿普索辛、CCDC80 和 ANGPTL4 水平可作为 IBD 早期胰岛素抵抗和动脉粥样硬化的重要标志物，尤其是 CD。
